3-SPA, also a Product of ALZ-801, Prevents Formation of Toxic Beta Amyloid Oligomers, the Key Driver of Alzheimer’s Disease FRAMINGHAM, Mass., July 14, 2019 – Alzheon, Inc., a [...]

Keynote Lectures at Neurotech, China Focus and Alzheimer’s Solutions Conference FRAMINGHAM, Mass., May 13, 2019 – Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio [...]

Keynote at World CNS Summit and Company Presentation at Noble Healthcare Conference FRAMINGHAM, Mass., January 21, 2019 – Alzheon, Inc., a clinical-stage biopharmaceutical company developing a [...]

Alzheon to Present Clinical Data at 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference FRAMINGHAM, Mass., October 24, 2018 – Alzheon, Inc., (Alzheon) a clinical [...]

Alzheon to Make Presentations at Upcoming Industry and Medical Conferences Company to Present Clinical Data at the 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference [...]

Publication Details Discovery of 3-Sulfopropanoic Acid, the Primary Metabolite of Tramiprosate and its Prodrug ALZ-801, in Cerebrospinal Fluid of Healthy Subjects as well as Alzheimer’s Patients [...]